Comment: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk
Restricted accessLetterFirst published online April, 2022
Comment: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk
BrosnahanSBChenXJCChungJ, et al. Low-dose tocilizumab with high-dose corticosteroids in patients hospitalized for COVID-19 hypoxic respiratory failure improves mortality without increased infection risk. Ann Pharmacother. Published June 28, 2021. doi:10.1177/10600280211028882
2.
ButtgereitFda SilvaJABoersM, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61:718-722. doi:10.1136/ard.61.8.718
3.
RECOVERY Collaborative Group; HorbyPLimWS, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693-704. doi:10.1056/NEJMoa2021436
4.
SebbaA. Tocilizumab: the first interleukin-6-receptor inhibitor. Am J Health Syst Pharm. 2008;65:1413-1418. doi:10.2146/ajhp070449
5.
YadavKLewisRJ. Immortal time bias in observational studies. JAMA. 2021;325:686-687. doi:10.1001/jama.2020.9151
6.
ShepshelovichDYahavDAmiRBGoldvaserHTauN. Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study. J Antimicrob Chemother. Published online June 2, 2021. doi:10.1093/jac/dkab163
